The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies

References

• Schwartz RS, Lenz G, Staudt, LM. Aggressive lymphomas. N Engl J Med. 2010;362(15):1417–1429.
   PubMed Web of Science ®Google Scholar
• Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119(9):1963–1971.
   PubMed Web of Science ®Google Scholar
• Mullighan CG. Genome sequencing of lymphoid malignancies. Blood. 2013;122(24):3899–3907.
   PubMed Web of Science ®Google Scholar
• Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209(9):1537–1551.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305–2315.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826–833.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495–501.
   PubMed Web of Science ®Google Scholar
• Gu X, Shivarov V, Strout MP. The role of activation-induced cytidine deaminase in lymphomagenesis. Curr Opin Hematol. 2012;19(4):292–298.
   PubMed Web of Science ®Google Scholar
• Liu M, Schatz DG. Balancing AID and DNA repair during somatic hypermutation. Trends Immunol. 2009;30(4):173–181.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Soong TD, Wang L, et al. Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma. PLoS One. 2012;7(7):e40332.
   PubMed Web of Science ®Google Scholar
• Khodabakhshi A, Morin R, Fejes A. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget. 2012;3(11):1308–1319.
   PubMed Web of Science ®Google Scholar
• Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109(10):3879–3884.
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181–185.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298–303.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013;122(7):1256–1265.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–119.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471(7337):189–195.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830–837.
   PubMed Web of Science ®Google Scholar
• Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659–2669.
   PubMed Web of Science ®Google Scholar
• Zhang J, Grubor V. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci. 2013;110(4):1398–1403.
   PubMed Web of Science ®Google Scholar
• Scott DW, Mungall KL, Ben-Neriah S, et al. TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood. 2012;119(21):4949–4952.
   PubMed Web of Science ®Google Scholar
• Alizadeh AAA, Eisen MBMB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S. 2003;100(17):9991–9996.
   PubMed Web of Science ®Google Scholar
• Ritz O, Guiter C, Castellano F, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood. 2009;114(6):1236–1242.
   PubMed Web of Science ®Google Scholar
• Okosun J, Bödör C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46(2):176–181.
   PubMed Web of Science ®Google Scholar
• Schuetz JM, Johnson NA, Morin RD, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia. 2012;26(6):1383–1390.
   PubMed Web of Science ®Google Scholar
• Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011;117(8):2451–2459.
   PubMed Web of Science ®Google Scholar
• Sneeringer CJ, Scott MP, Kuntz KW, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S. 2010;107(49):20980–20985.
   PubMed Web of Science ®Google Scholar
• Dubois S, Mareschal S, Picquenot J-M, et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget. 2015;6:16712–16724.
   Web of Science ®Google Scholar
• Bödör C, Grossmann V. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122(18):3165–3168.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Shin DH, Bin KK, et al. Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma. 2014;55(9):2056–2063.
   PubMed Web of Science ®Google Scholar
• Zhang J, Dominguez-Sola D, Hussein S, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21:1190–1198.
   PubMed Web of Science ®Google Scholar
• Ortega-Molina A, Boss IW, Canela A, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. 2015;21:1199–1208.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.
   PubMed Web of Science ®Google Scholar
• Bohers E, Mareschal S, Bouzelfen A, et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes. Chromosomes Cancer. 2014;53(2):144–153.
   PubMed Web of Science ®Google Scholar
• Dubois S, Viailly P-J, Mareschal S, et al. Recurrent somatic mutations in Diffuse Large B Cell Lymphoma assessed by high-throughput targeted sequencing highlight molecular subtypes’ genetic divergence: a LYSA study. In: 13th International conference on malignant lymphoma. Lugano; 2015.
   Google Scholar
• Ngo VN, Davis RE, Lamy L, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature. 2006;441(7089):106–110.
   PubMed Web of Science ®Google Scholar
• Davis RE. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861–1874.
   PubMed Web of Science ®Google Scholar
• Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676–1679.
   PubMed Web of Science ®Google Scholar
• Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717–721.
   PubMed Web of Science ®Google Scholar
• Fernández-Rodríguez C, Bellosillo B, García-García M, et al. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. Leukemia. 2014;28(10):2104–2106.
   PubMed Web of Science ®Google Scholar
• Kim Y, Ju H, Kim DH, et al. CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Hum Pathol. 2014;45(3):556–564.
   PubMed Web of Science ®Google Scholar
• Mareschal S, Lanic H, Ruminy P, et al. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011;96(12):1888–1890.
   PubMed Web of Science ®Google Scholar
• Choi J-W, Kim Y, Lee J-H, et al. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol. 2013;44(7):1375–1381.
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785.
   PubMed Web of Science ®Google Scholar
• Koens L, Zoutman WH, Ngarmlertsirichai P, et al. Nuclear factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol. 2014;134(1):290–292.
   PubMed Web of Science ®Google Scholar
• Pham-Ledard A, Cappellen D, Martinez F, et al. MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2012;132(8):2118–2120.
   PubMed Web of Science ®Google Scholar
• Pham-Ledard A, Beylot-Barry M, Barbe C, et al. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol. 2014;150(11):1173–1179.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aguilar A, Idbaih A, Boisselier B, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18(19):5203–5211.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2015. [Epub ahead of print].
   PubMedGoogle Scholar
• Montesinos-Rongen M, Schmitz R, Brunn A, et al. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol. 2010;120(4):529–535.
   PubMed Web of Science ®Google Scholar
• Bruno A, Boisselier B, Labreche K, et al. Mutational analysis of primary central nervous system lymphoma. Oncotarget. 2014;5(13):5065–5075.
   PubMed Web of Science ®Google Scholar
• Braggio E, Van Wier S, Ojha J, et al. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res. 2015;21(17):3986–3994.
   PubMed Web of Science ®Google Scholar
• Kraan W, Van Keimpema M, Horlings HM, et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia. 2014;28(3):719–720.
   PubMed Web of Science ®Google Scholar
• Capello D, Gloghini A, Martini M, et al. Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas. Br J Haematol. 2011;152(6):777–780.
   PubMed Web of Science ®Google Scholar
• Mathews Griner LA, Guha R, Shinn P, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S. 2014;111(6):2349–2354.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926.
   PubMed Web of Science ®Google Scholar
• Yuan J, Wright G, Rosenwald A, et al. Identification of primary mediastinal large B-cell lymphoma at nonmediastinal sites by gene expression profiling. Am J Surg Pathol. 2015;39:1322–1330.
   PubMed Web of Science ®Google Scholar
• Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin’s lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29(11):1411–1421.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851–862.
   PubMed Web of Science ®Google Scholar
• Melzner I, Bucur AJ, Brüderlein S, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105(6):2535–2542.
   PubMed Web of Science ®Google Scholar
• Melzner I, Weniger MA, Bucur AJ, et al. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer. 2006;118(8):1941–1944.
   PubMed Web of Science ®Google Scholar
• Gunawardana J, Chan FC, Telenius A, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet. 2014;46(4):329–335.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Hansmann M-L, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med. 2009;206(5):981–989.
   PubMed Web of Science ®Google Scholar
• Momose S, Weißbach S, Pischimarov J, et al. The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. Leukemia. 2015;29:1789–1791.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6(1):130–140.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2013;11(1):12–23.
   PubMed Web of Science ®Google Scholar
• Novak AJ, Asmann YW, Maurer MJ, et al. Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. Blood Cancer J. 2015;5(8):e346.
   PubMed Web of Science ®Google Scholar
• Mareschal S, Dubois S, Viailly P-J, et al. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. Genes, Chromosomes Cancer; 2015.
   Web of Science ®Google Scholar
• Clozel T, Yang S, Elstrom RL, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 2013;3(9):1002–1019.
   PubMed Web of Science ®Google Scholar
• Lykkegaard Andersen C, Asmar F, Klausen T, et al. Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. Leuk Res Rep. 2013;2(1):1–3.
   Google Scholar
• Chaidos A, Caputo V, Karadimitris A. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol. 2015;6(3):128–141.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Soria J, Reyderman L, et al. Phase 1 study of E7438 (EPZ-6438), an enhancer of Zeste Homolog 2 (EZH2) inhibitor: dose determination and preliminary activity in non-Hodgkin lymphoma. In: 13th International conference on malignant lymphoma. Lugano; 2015.
   Google Scholar
• Zhao X, Lwin T, Zhang X, et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia. 2013;27(12):2341–2350.
   PubMed Web of Science ®Google Scholar
• Ceribelli M, Kelly PN, Shaffer AL, et al. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S. 2014;111(31):11365–11370.
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Grau M, Lenze D, et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S. 2013;110(30):12420–12425.
   PubMed Web of Science ®Google Scholar
• Kloo B, Nagel D, Pfeifer M, et al. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2011;108(1):272–277.
   PubMed Web of Science ®Google Scholar
• Younes A, Salles G, Bociek RG, et al. An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma. In: 56th ASH annual meeting and exposition. San Francisco (CA); 2014.
   Google Scholar
• Wanner K, Hipp S, Oelsner M, et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol. 2006;134(5):475–484.
   PubMed Web of Science ®Google Scholar
• Barnes JA, Jacobsen E, Feng Y, et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013;98(4):615–619.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25(2):341–347.
   PubMed Web of Science ®Google Scholar
• Zheng X, Ding N, Song Y, et al. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment. Cancer Cell Int. 2014;14(1):32.
   PubMed Web of Science ®Google Scholar
• Naylor TL, Tang H, Ratsch BA, et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res. 2011;71(7):2643–2653.
   PubMed Web of Science ®Google Scholar
• Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol. 2011;223(2):263–274.
   Web of Science ®Google Scholar
• Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it’s NOTCH what you think. J Exp Med. 2011;208(10):1931–1935.
   PubMed Web of Science ®Google Scholar
• Rossi D, Ciardullo C, Gaidano G. Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies. Semin Cancer Biol. 2013;23(6):422–430.
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101–105.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Rossi D, Lucioni M, et al. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. Haematologica. 2015;100(2):246–252.
   PubMed Web of Science ®Google Scholar
• López-Guerra M, Xargay-Torrent S, Rosich L, et al. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia. 2014;29(1):96–106.
   PubMed Web of Science ®Google Scholar
• Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(8):1073–1081.
   PubMed Web of Science ®Google Scholar
• Kircher M, Witten DM, Jain P, et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310–315.
   PubMed Web of Science ®Google Scholar
• Viailly P-J, Mareschal S, Bertrand P, et al. GenerateReports : an IonTorrent plugin summarizing a whole NGS experiment for clinical interpretation. In: ISMB/ECCB. Dublin; 2015.
   Google Scholar
• Bohers E, Mareschal S, Bertrand P, et al. Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era. Leuk Lymphoma. 2014;56(5):1213–1222.
   Web of Science ®Google Scholar
• Challa-Malladi M, Lieu Y, Califano O, et al. Combined genetic inactivation of β2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011;20(6):728–740.
   PubMed Web of Science ®Google Scholar
• Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471(7338):377–381.
   PubMed Web of Science ®Google Scholar
• Trinh DL, Scott DW, Morin RD, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121(18):3666–3674.
   PubMed Web of Science ®Google Scholar
• Muppidi JR, Schmitz R, Green JA, et al. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature. 2014;516(7530):254–258.
   PubMed Web of Science ®Google Scholar
• Yang Y, Shaffer AL, Emre NCT, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6):723–737.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006;203(2):311–317.
   PubMed Web of Science ®Google Scholar
• Young KH, Leroy K, Møller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008;112(8):3088–3098.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: a report from an International DLBCL Rituximab-CHOP Consortium Program study. Blood. 2012;120(19):3986–3997.
   PubMed Web of Science ®Google Scholar
• Bohers E, Viailly PJ, Dubois S, et al. Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica. 2015;100:e280-e284. DOI:10.3324/haematol.2015.123612.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright GW, Emre NCT, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S. 2008;105(36):13520–13525.
   PubMed Web of Science ®Google Scholar
• Boeva V, Popova T, Lienard M, et al. Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data. Bioinformatics. 2014;30(24):3443–3450.
   PubMed Web of Science ®Google Scholar
• Mareschal S, Ruminy P, Bagacean C, et al. Accurate classification of germinal center B-cell-like/activated B-cell-like diffuse large B-cell lymphoma using a simple and rapid reverse transcriptase-multiplex ligation-dependent probe amplification assay: a CALYM study. J Mol Diagn. 2015;17:273–283.
   Web of Science ®Google Scholar
• Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848–2856.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–586.
   PubMed Web of Science ®Google Scholar
• He J, Wu J, Jiao Y, et al. IgH gene rearrangements as plasma biomarkers in Non-Hodgkin’s lymphoma patients. Oncotarget. 2011;2(3):178–185.
   PubMed Web of Science ®Google Scholar
• Hosny G, Farahat N, Hainaut P. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin’s lymphoma. Cancer Lett. 2009;275(2):234–239.
   PubMed Web of Science ®Google Scholar
• Mussolin L, Burnelli R, Pillon M, et al. Plasma cell-free DNA in paediatric lymphomas. J Cancer. 2013;4(4):323–329.
   PubMed Web of Science ®Google Scholar
• Jones K, Nourse JP, Keane C, et al. Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. Am J Hematol. 2012;87(3):258–265.
   PubMed Web of Science ®Google Scholar
• Hohaus S, Giachelia M, Massini G, et al. Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol. 2009;20(8):1408–1413.
   PubMed Web of Science ®Google Scholar
• Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125(24):3679–3687.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541–549.
   PubMed Web of Science ®Google Scholar